Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma

Abstract

Esophageal carcinoma (EC) is a malignancy with high metastatic potential. Chromosomal helicase/ATPase DNA binding protein 1-like (CHD1L) gene is a newly identified oncogene located at Chr1q21, and it is amplified in many solid tumors. However, the status of CHD1L protein expression in EC and its clinical significance is uncertain. This study was designed to investigate the significance of CHD1L expression in human EC and its biological function in EC cells. The expression of CHD1L was examined by immunohistochemistry in 191 surgically resected ECs. The associations between CHD1L expression and clinical pathological parameters and the prognostic value of CHD1L were analyzed. Western blot analysis showed that CHD1L was overexpressed in EC cell lines. In addition, positive CHD1L expression was strongly related to advanced clinical stage (P<0.01), and lymph node metastasis (P<0.01) of EC. The Kaplan-Meier curve indicated that high expression of CHD1L may result in poor prognosis of EC patients (P<0.01), and multivariate analysis showed that CHD1L overexpression was an independent predictor of overall survival. Furthermore, suppression of CHD1L in EC cells increased apoptosis and decreased cell proliferation invasion ability. Our results suggest that CHD1L is a target oncogene with the potential to serve as a novel prognostic biomarker in EC pathogenesis.

Prognostic role of chromodomain helicase DNA binding protein 1-like protein in human solid cancers

“…According to the inclusion and exclusion criteria mentioned above, finally, a total of 14 publications that up to the inclusion norm were selected for this meta-analysis. [ 11 – 24 ] All those eligible articles included 2597 patients with a median sample-size of 185.5 (ranged from 53 to 616). Among the 14 publications, there were totally eleven different kinds of solid tumors, including pancreatic cancer (PC), hepatocellular carcinoma (HCC), breast cancer (BC), nonsmall-cell lung cancer (NSCLC), esophageal carcinoma (EC), nasopharyngeal carcinoma (NPC), gastric cancer (GC), colorectal carcinoma (CRC), ovarian carcinomas (OC), glioma, and bladder cancer.…”

Diversity roles of CHD1L in normal cell function and tumorigenesis

“…Importantly, CHD1L shows carcinogenicity in the process of malignant transformation. CHD1L overexpression in cancer cells is considered as a biomarker of short tumor-free survival time and poor prognosis [ 12 , 20 – 28 ].…”

“…It is documented that CHD1L is deregulation in various neoplastic diseases. CHD1L is an important oncoprotein that is overexpressed in various malignant tumors, including HCC [ 1 , 14 – 18 , 21 ], ovarian cancer [ 23 ], gastric cancer [ 22 ], colorectal carcinoma [ 24 ], bladder cancer [ 25 ], breast cancer [ 4 , 26 , 63 ], nasopharyngeal carcinoma [ 27 ], glioma [ 64 ], NSCLC [ 12 , 66 ], myeloma [ 6 ], pancreatic cancer [ 65 ], esophageal carcinoma [ 28 , 67 ] and cholangiocarcinoma [ 20 , 103 ] (Fig. 4 and Table 3 ).…”

The high expression of CHD1L and its clinical significance in human solid tumors

“…A growing number of studies have shown that CHD1L is also significantly up-regulated in other cancers, such as breast cancer, [ 7 ] gastric cancer, [ 8 ] esophageal carcinoma, [ 9 ] and so on, which can be used as a cancer-promoting factor and have an impact on diagnosis and treatment. Many researchers reported that CHD1L is associated with tumor initiation and progression, suggesting that it is associated with cancer prognosis.…”